This study aims to accurately classify ATN profiles using highly specific amyloid and tau PET ligands and MRI in patients with cognitive impairment and suspected Alzheimer’s disease (AD). The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.